OPKO Health, Inc.
NASDAQ:OPKBiotechnology
+$0.01 today
- Market cap
- $1.25B
- Beta
- 1.49
- P/E (TTM)
- -5.1
- EPS (TTM)
- -$0.28
Volume 3.06M
Average 2.59M
OPK Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
OPKO Health, Inc.NASDAQ: OPK
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow growth accelerates
Q1 FY2026 financing cash flow of $5.16M (cash outflow) rose 28.2% year over year, ahead of the -174.7% change in trailing-twelve-month financing cash flow. Sequentially, it fell 71.9% from the prior quarter.
Context
- Financing cash flow amounted to 19.5% of revenue in FY2025, down 6.4 pp from a year earlier.
- Financing cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +28.2% holds above the trailing-twelve-month pace of -174.7%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (118.06M) USD
- Year-over-year change
- -164.1%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (118.06M) | -164.1% |
| FY2024 | 2024-12-31 | 184.17M | +1729.4% |
| FY2023 | 2023-12-31 | (11.3M) | -149.2% |
| FY2022 | 2022-12-31 | 22.97M | +321.9% |
| FY2021 | 2021-12-31 | (10.35M) | — |
Financing Cash Flow vs competitors
How OPK compares with its peers on the latest reported figures
- OPK's LTM Mar 2026 financing cash flow of $119.19M is the 4th largest of the 11 companies compared; the peer median is $36.02M.
- Its year-over-year change of -174.7% is the lowest of 10, against a peer median of +94.9%.
- Financing cash flow amounts to 20.5% of revenue for OPK, versus a peer median of 13.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $748.48M | +1272.6% | — | 58.5% | |
BLLNBillionToOne, Inc. | LTM Jun 2026 | $326.54M | — | — | 82.2% |
| LTM Mar 2026 | $128.08M | -4.2% | +357.0% | 198.5% | |
| LTM Mar 2026 | $119.19M | -174.7% | — | 20.5% | |
| LTM Jun 2026 | $50.31M | +94.9% | -53.8% | 1.9% | |
| LTM Mar 2026 | $48.45M | +266.7% | -42.3% | 15.1% | |
| LTM Mar 2026 | $47.6M | +217.3% | — | 5.7% | |
| LTM Mar 2026 | $24.44M | +3997.4% | — | 35.7% | |
| FY2025 | $12.7M | -71.5% | -15.1% | 11.8% | |
| LTM Jun 2026 | $11.39M | -94.3% | — | 1.5% | |
| LTM Mar 2026 | $10.44M | +72.3% | — | 3.1% | |
| Peer median (excluding OPK) | $36.02M | +94.9% | -28.7% | 13.4% | |
Competitors are the stored peer set for OPK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (30.14M) | (328.41M) | (188.86M) | (53.22M) | (225.68M) |
| Depreciation & Amortization | 78.72M | 108.66M | 105.3M | 98.18M | 91.63M |
| Deferred Income Tax | 10.16M | (74.41M) | 146K | 14.74M | (15M) |
| Stock-Based Compensation | 13.63M | 18.51M | 11.41M | 11.05M | 10.71M |
| Change in Working Capital | (20.48M) | 42.65M | 21.8M | 32.18M | (41.18M) |
| Accounts Receivables | 5.23M | 128.6M | 3.41M | (220K) | 30.21M |
| Inventory | 30.68M | 13.66M | 15.2M | 4.22M | (4.12M) |
| Accounts Payables | (10.85M) | (9.39M) | 2.83M | (20.66M) | (14.22M) |
| Other Working Capital | (45.55M) | (90.22M) | 363K | 48.84M | (53.06M) |
| Other Non-Cash Items | (13.55M) | 137.8M | 22.01M | (286.41M) | 976K |
| Operating Cash Flow | 38.34M | (95.19M) | (28.2M) | (183.49M) | (178.54M) |
| Capital Expenditures | (32.16M) | (24.58M) | (16.28M) | (25.01M) | (12.28M) |
| Acquisitions (Net) | (6M) | (1.76M) | (5M) | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 8.08M | 115.42M | 364K | 166.6M | 52.18M |
| Other Investing Activities | 66.03M | 1.95M | 2.71M | 210.62M | 190.39M |
| Investing Cash Flow | 35.95M | 91.04M | (18.2M) | 352.21M | 230.3M |
| Debt Repayment | (11.24M) | 23.75M | (11.03M) | 287.98M | (70.76M) |
| Common Stock Issued | 0 | 0 | 0 | 0 | (256K) |
| Common Stock Repurchased | 0 | 0 | 0 | (90.22M) | (47.04M) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 893K | (774K) | (272K) | (13.59M) | 0 |
| Financing Cash Flow | (10.35M) | 22.97M | (11.3M) | 184.17M | (118.06M) |
| Effect of Forex Changes | (1.44M) | (339K) | 388K | (3.16M) | 3.43M |
| Net Change in Cash | 62.5M | 18.48M | (57.31M) | 349.73M | (62.87M) |
| Free Cash Flow | 6.18M | (119.77M) | (44.47M) | (208.5M) | (190.82M) |
OPKO Health, Inc.
NASDAQ:OPK
Intrinsic Alpha fair value
Locked
Current Price
$1.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.